(NASDAQ: KYMR) Kymera Therapeutics's forecast annual revenue growth rate of -35.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.51%.
Kymera Therapeutics's revenue in 2026 is $104,999,000.On average, 24 Wall Street analysts forecast KYMR's revenue for 2026 to be $8,929,544,867, with the lowest KYMR revenue forecast at $7,904,297,747, and the highest KYMR revenue forecast at $12,135,832,697. On average, 24 Wall Street analysts forecast KYMR's revenue for 2027 to be $3,388,387,684, with the lowest KYMR revenue forecast at -$1,059,338,873, and the highest KYMR revenue forecast at $8,550,378,049.
In 2028, KYMR is forecast to generate $3,317,460,206 in revenue, with the lowest revenue forecast at -$2,037,190,141 and the highest revenue forecast at $8,108,515,665.